Corvus Pharmaceuticals, Inc. (Nasdaq: CRVS) announced results of three preclinical studies of CPI-444, the Company’s lead oral checkpoint inhibitor. The ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE